Form D · Biotechnology
Asher Biotherapeutics, Inc.
South San Francisco, CA · CIK 0001787260
Offering snapshot reported Apr 16, 2024 · SEC filing
- Reported sold
- $55M Offering amount: $55M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 3, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 16, 2024 | Initial | $54,999,990 | No comparison | 16 | SEC filing |
| Sep 7, 2021 | Initial | $107,999,975 | No comparison | Not reported | SEC filing |
| Sep 5, 2019 | Initial | $490,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-510726
Source: Form D, filed Apr 16, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ian Clark | Director |
| Bob Deresiewicz | Director |
| Ivana Djuretic | Director, Executive |
| Kyle Elrod | Executive |
| Craig Gibbs | Director, Executive |
| Reid Huber | Director |
| Don O'sullivan | Executive |
| Elaine Sun | Director |
| Jeffrey Tong | Director |
| Yik Andy Yeung | Executive |
| Andy Yeung | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
650 Gateway Blvd., Suite 100
South San Francisco, CA, 94080
South San Francisco, CA, 94080